TABLE OF CONTENTS

1. INTRODUCTION 28
1.1. OBJECTIVES OF THE STUDY 28
1.2. MARKET DEFINITION 28
1.3. OVERVIEW OF GLOBAL CHOLESTEROL TESTING MARKET 28
1.4. CURRENCY AND PRICING 29
1.5. LIMITATION 29
1.6. MARKETS COVERED 30
2. MARKET SEGMENTATION 32
2.1. MARKETS COVERED 32
2.2. GEOGRAPHIC SCOPE 33
2.3. YEARS CONSIDERED FOR THE STUDY 34
2.4. CURRENCY AND PRICING 34
2.5. RESEARCH METHODOLOGY 35
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.7. SECONDARY SOURCES 39
2.8. ASSUMPTIONS 39
3. EXECUTIVE SUMMARY 40
4. MARKET OVERVIEW 43
4.1. DRIVERS 45
4.1.1. TECHNOLOGICAL ADVANCEMENTS IN CHOLESTEROL TESTING 45
4.1.2. GROWING NUMBER OF CARDIOVASCULAR DISEASES AND OBESITY 45
4.1.3. HIGHER GROWING NUMBER OF GERIATRIC POPULATION 46
4.1.4. RISING AWARENESS AND ACCEPTANCE OF PREVENTIVE HEALTHCARE 46
4.1.5. INCREASING CHOLESTEROL HOME/SELF-TESTING MARKET 47
?
4.2. RESTRAINTS 48
4.2.1. LACK OF KNOWLEDGE ABOUT NEW TREATMENT PRACTICES 48
4.2.2. REGULATORY POLICIES 48
4.3. OPPORTUNITIES 49
4.3.1. HIGH GROWTH POSSIBLITY IN DEVELOPING COUNTRIES 49
4.3.2. PATIENT-INITIATED TESTING 49
4.4. CHALLENGES 50
4.4.1. PATIENT DATA SECURITY 50
5. PREMIUM INSIGHTS 51
6. GLOBAL CHOLESTEROL TESTING MARKET, BY PRODUCT TYPE 54
6.1. OVERVIEW 55
6.2. TESTING STRIPS 57
6.3. TEST KITS 58
7. GLOBAL CHOLESTEROL TESTING MARKET, BY TEST 59
7.1. OVERVIEW 60
7.2. LIPID PANEL TEST/COMPLETE LIPID PROFILE 62
7.2.1. TOTAL CHOLESTEROL TEST 63
7.2.2. HDL CHOLESTEROL TEST 63
7.2.3. LDL CHOLESTEROL TEST 64
7.2.4. TRIGLYCERIDES/VLDL CHOLESTEROL TEST 64
7.3. APOLIPOPROTEIN B TEST 65
7.4. APOLIPOPROTEIN A-1 TEST 66
7.5. APOE GENOTYPING TEST 67
7.6. APOLIPOPROTEIN CII 68
7.7. OTHERS 69
?
8. GLOBAL CHOLESTEROL TESTING MARKET, BY TEST TYPE 70
8.1. OVERVIEW 71
8.2. NON-INVASIVE 73
8.3. INVASIVE 74
9. GLOBAL CHOLESTEROL TESTING MARKET, BY PRESCRIPTION MODE 75
9.1. OVERVIEW 76
9.2. OVER THE COUNTER 78
9.3. PRESCRIPTION BASED 79
10. GLOBAL CHOLESTEROL TESTING MARKET, BY END-USERS 80
10.1. OVERVIEW 81
10.2. CLINICS 83
10.3. HOSPITALS 84
10.4. AMBULATORY CENTERS 85
10.5. HOMECARE 86
10.6. DIAGNOSTIC CENTERS 87
11. GLOBAL CHOLESTEROL TESTING MARKET BY GEOGRAPHY 88
11.1. OVERVIEW 89
11.2. NORTH AMERICA 96
11.2.1. U.S. 106
11.2.2. CANADA 109
11.2.3. MEXICO 112
11.3. EUROPE 115
11.3.1. GERMANY 125
11.3.2. FRANCE 128
11.3.3. U.K. 132
11.3.4. ITALY 135
11.3.5. SPAIN 138
11.3.6. SWITZERLAND 141
11.3.7. NETHERLANDS 144
11.3.8. BELGIUM 147
11.3.9. RUSSIA 150
11.3.10. TURKEY 153
11.3.11. REST OF EUROPE 156
11.4. ASIA-PACIFIC 157
11.4.1. JAPAN 167
11.4.2. CHINA 170
11.4.3. INDIA 173
11.4.4. SOUTH KOREA 176
11.4.5. AUSTRALIA 179
11.4.6. SINGAPORE 182
11.4.7. THAILAND 185
11.4.8. MALAYSIA 188
11.4.9. INDONESIA 191
11.4.10. PHILIPPINES 194
11.4.11. REST OF ASIA-PACIFIC 197
11.5. SOUTH AMERICA 198
11.5.1. BRAZIL 208
11.5.2. REST OF SOUTH AMERICA 211
11.6. MIDDLE EAST AND AFRICA 212
11.6.1. SOUTH AFRICA 222
11.6.2. REST OF MIDDLE EAST AND AFRICA 225
12. GLOBAL CHOLESTEROL TESTING MARKET, COMPANY LANDSCAPE 226
12.1. COMPANY SHARE ANALYSIS; GLOBAL 226
12.2. COMPANY SHARE ANALYSIS; NORTH AMERICA 227
12.3. COMPANY SHARE ANALYSIS; EUROPE 228
12.4. COMPANY SHARE ANALYSIS; ASIA PACIFIC 229
13. COMPANY PROFILES 230
13.1. BIO-RAD LABORATORIES, INC. 230
13.1.1. COMPANY OVERVIEW 230
13.1.2. BIO-RAD LABORATORIES, INC.; REVENUE ANALYSIS 230
13.1.3. PRODUCT PORTFOLIO 231
13.1.4. RECENT DEVELOPMENTS 231
13.2. ABBOTT 232
13.2.1. COMPANY OVERVIEW 232
13.2.2. ABBOTT; REVENUE ANALYSIS 232
13.2.3. PRODUCT PORTFOLIO 233
13.2.4. RECENT DEVELOPMENTS 233
13.3. SIEMENS AG 234
13.3.1. COMPANY OVERVIEW 234
13.3.2. SIEMENS AG; REVENUE ANALYSIS 234
13.3.3. PRODUCT PORTFOLIO 235
13.3.4. RECENT DEVELOPMENTS 235
13.4. ALERE INC. 236
13.4.1. COMPANY OVERVIEW 236
13.4.2. ALERE INC.; REVENUE ANALYSIS 236
13.4.3. PRODUCT PORTFOLIO 237
13.4.4. RECENT DEVELOPMENTS 237
13.5. SIGMA ALDRICH (A SUBSIDIARY OF MERCK KGAA) 238
13.5.1. COMPANY OVERVIEW 238
13.5.2. MERCK KGAA; REVENUE ANALYSIS 238
13.5.3. PRODUCT PORTFOLIO 239
13.5.4. RECENT DEVELOPMENTS 239
?
13.6. F. HOFFMANN-LA ROCHE LTD 240
13.6.1. COMPANY OVERVIEW 240
13.6.2. F. HOFFMANN-LA ROCHE LTD;REVENUE ANALYSIS 240
13.6.3. PRODUCT PORTFOLIO 241
13.6.4. RECENT DEVELOPMENTS 241
13.7. DANAHER 242
13.7.1. COMPANY OVERVIEW 242
13.7.2. DANAHER; REVENUE ANALYSIS 242
13.7.3. PRODUCT PORTFOLIO 243
13.7.4. RECENT DEVELOPMENTS 243
13.8. QUEST DIAGNOSTICS INCORPORATED 244
13.8.1. COMPANY OVERVIEW 244
13.8.2. QUEST DIAGNOSTICS INCORPORATED; REVENUE ANALYSIS 244
13.8.3. PRODUCT PORTFOLIO 245
13.8.4. RECENT DEVELOPMENTS 245
13.9. ACCUTECH, LLC 246
13.9.1. COMPANY OVERVIEW 246
13.9.2. ACCUTECH, LLC; COMPANY SNAPSHOT 246
13.9.3. PRODUCT PORTFOLIO 246
13.9.4. RECENT DEVELOPMENTS 246
13.10. PRIMA LAB SA 247
13.10.1. COMPANY OVERVIEW 247
13.10.2. PRIMA LAB SA; COMPANY SNAPSHOT 247
13.10.3. PRODUCT PORTFOLIO 247
13.10.4. RECENT DEVELOPMENTS 247
13.11. HOME ACCESS HEALTH CORPORATION 248
13.11.1. COMPANY OVERVIEW 248
13.11.2. HOME ACCESS HEALTH CORPORATION; COMPANY SNAPSHOT 248
13.11.3. PRODUCT PORTFOLIO 248
13.11.4. RECENT DEVELOPMENTS 248
13.12. EUROFINS SCIENTIFIC 249
13.12.1. COMPANY OVERVIEW 249
13.12.2. EUROFINS SCIENTIFIC; REVENUE ANALYSIS 249
13.12.3. PRODUCT PORTFOLIO 250
13.12.4. RECENT DEVELOPMENTS 250
13.13. RANDOX LABORATORIES LTD. 251
13.13.1. COMPANY OVERVIEW 251
13.13.2. RANDOX LABORATORIES LTD.; COMPANY SNAPSHOT 251
13.13.3. PRODUCT PORTFOLIO 251
13.13.4. RECENT DEVELOPMENTS 251
13.14. PTS DIAGNOSTICS 252
13.14.1. COMPANY OVERVIEW 252
13.14.2. PTS DIAGNOSTIC; COMPANY SNAPSHOT 252
13.14.3. PRODUCT PORTFOLIO 253
13.14.4. RECENT DEVELOPMENTS 253
14. RELATED REPORTS 254